Archynetys Live news trend intelligence
▲ Peaking Business

Thyme Care raises $125 million, pushing cancer care startup's valuation above $2 billion

Thyme Care secures a $125 million Series E round, elevating its valuation past $2 billion.

6sources
6articles
4velocity
+84%since first seen
14h agofirst detected

Evidence dossier

Intelligence passport

54/100 Publishable
6distinct sources shown
14velocity measurements
1language editions checked
All brief claims passed the second-source checkbrief evidence status

Measured timeline

  1. Detected The first matching coverage entered the Archynetys cluster.
  2. Latest coverage observed Most recent article currently attached to this story cluster.
  3. Peak measured velocity The recorded velocity reached 4.
  4. Evidence threshold reached The story had enough independent coverage for an explanatory brief.

Source diversity sample: Nashville Post · Dealroom · Pulse 2.0 · MedCity News · Fierce Healthcare · CNBC.

How this dossier is built: methodology · AI policy · corrections.

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Where it stands

Oncology company Thyme Care has raised $125 million in a Series E funding round, pushing its valuation above $2 billion. Financial backing for the round comes from investors including Morgan Health, Humana, and CVS Health Ventures, according to reports from Fierce Healthcare and CNBC.

Alongside the funding, the startup has launched a new oncology parent entity and holding company named Thyme Companies, as detailed by Dealroom, Pulse 2.0, and MedCity News. Coverage does not yet specify how the newly acquired capital will be allocated or what specific operational changes will follow the creation of the parent entity.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 2h ago.

The reporting (6)

Answered

How much did Thyme Care raise?

Thyme Care raised $125 million in a Series E round.

What is Thyme Care's valuation?

The funding round pushed the startup's valuation above $2 billion.

What new entity was launched?

The company launched a new oncology parent entity and holding company called Thyme Companies.

Topics

Thyme Care Series E Oncology Venture Capital Healthcare

From around our network

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →